Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to ...

Arrowhead Pharmaceuticals strikes a $130M+ deal with Sanofi for plozasiran in Greater China, targeting high triglyceride ...

US RNA interference (RNAi)specialist Arrowhead Pharmaceuticals (Nasdaq: ARWR) today announced that its majority-owned subsidiary Visirna Therapeutics has signed an asset purchase agreement with France ...

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

Sanofi will acquire rights to develop and commercialize the drug for $130 million upfront, with Visirna eligible for up to $265 million in milestone payments.

Viking Therapeutics jumped by 9.74 percent on Tuesday to close at $30.19 apiece as investors repositioned portfolios ahead of the expected release of the results of its own weight loss drug ...

Bicycle Therapeutics BCYC underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below summarizes their recent ratings ...

By Kelly Cloonan Century Therapeutics plans to cut 51% of its employees as it looks to focus on programs with the highest potential for value.

The majority of liver cancer cases could be prevented by reducing levels of viral hepatitis, alcohol consumption and MASLD (metabolic dysfunction-associated steatotic liver disease – previously called ...

Investing.com -- MiNK Therapeutics, Inc. (NASDAQ: INKT) stock soared 200% after the company announced a complete remission in a patient with metastatic testicular cancer following treatment with ...

Sarepta Therapeutics announced a layoff of 493 employees, including 80 in Franklin County, amid restructuring efforts and criticism from the FDA.

MiNK Therapeutics shares jumped as new clinical data show durable remission in testicular cancer and tumor reduction in gastric cancer using its iNKT cell therapy, agenT-797, in combination with ...